[1] R.A. Patchell, P.A. Tibbs, W.F. Regine, R.J. Dempsey, M. Mohiuddin, R.J. Kryscio, W.R. Markesbery, K.A. Foon, B. Young, Postoperative Radiotherapy in the Treatment of Single Metastases to the Brain: A Randomized Trial, JAMA. 280 (1998). https://doi.org/10.1001/jama.280.17.1485.
[2] H.M. Specht, S.E. Combs, Stereotactic radiosurgery of brain metastases, J Neurosurg Sci. 60 (2016) 357–366.
[3] M. Doré, S. Martin, G. Delpon, K. Clément, L. Campion, F. Thillays, Stereotactic radiotherapy following surgery for brain metastasis: Predictive factors for local control and radionecrosis, Cancer/Radiothérapie. 21 (2017) 4–9. https://doi.org/10.1016/j.canrad.2016.06.010.
[4] M. Kocher, R. Soffietti, U. Abacioglu, S. Villà, F. Fauchon, B.G. Baumert, L. Fariselli, T. Tzuk-Shina, R.-D. Kortmann, C. Carrie, M.B. Hassel, M. Kouri, E. Valeinis, D. van den Berge, S. Collette, L. Collette, R.-P. Mueller, Adjuvant Whole-Brain Radiotherapy Versus Observation After Radiosurgery or Surgical Resection of One to Three Cerebral Metastases: Results of the EORTC 22952-26001 Study, JCO. 29 (2011) 134–141. https://doi.org/10.1200/JCO.2010.30.1655.
[5] P.D. Brown, K.V. Ballman, J.H. Cerhan, S.K. Anderson, X.W. Carrero, A.C. Whitton, J. Greenspoon, I.F. Parney, N.N.I. Laack, J.B. Ashman, J.-P. Bahary, C.G. Hadjipanayis, J.J. Urbanic, F.G. Barker, E. Farace, D. Khuntia, C. Giannini, J.C. Buckner, E. Galanis, D. Roberge, Postoperative stereotactic radiosurgery compared with whole brain radiotherapy for resected metastatic brain disease (NCCTG N107C/CEC·3): a multicentre, randomised, controlled, phase 3 trial, The Lancet Oncology. 18 (2017) 1049–1060. https://doi.org/10.1016/S1470-2045(17)30441-2.
[6] S. Scoccianti, U. Ricardi, Treatment of brain metastases: Review of phase III randomized controlled trials, Radiotherapy and Oncology. 102 (2012) 168–179. https://doi.org/10.1016/j.radonc.2011.08.041.
[7] J. Li, S.M. Bentzen, J. Li, M. Renschler, M.P. Mehta, Relationship Between Neurocognitive Function and Quality of Life After Whole-Brain Radiotherapy in Patients With Brain Metastasis, International Journal of Radiation Oncology*Biology*Physics. 71 (2008) 64–70. https://doi.org/10.1016/j.ijrobp.2007.09.059.
[8] G. Welzel, K. Fleckenstein, J. Schaefer, B. Hermann, U. Kraus-Tiefenbacher, S.K. Mai, F. Wenz, Memory Function Before and After Whole Brain Radiotherapy in Patients With and Without Brain Metastases, International Journal of Radiation Oncology*Biology*Physics. 72 (2008) 1311–1318. https://doi.org/10.1016/j.ijrobp.2008.03.009.
[9] R. Soffietti, U. Abacioglu, B. Baumert, S.E. Combs, S. Kinhult, J.M. Kros, C. Marosi, P. Metellus, A. Radbruch, S.S. Villa Freixa, M. Brada, C.M. Carapella, M. Preusser, E. Le Rhun, R. Rudà, J.C. Tonn, D.C. Weber, M. Weller, Diagnosis and treatment of brain metastases from solid tumors: guidelines from the European Association of Neuro-Oncology (EANO), Neuro-Oncology. 19 (2017) 162–174. https://doi.org/10.1093/neuonc/now241.
[10] S. Scharl, A. Kirstein, K.A. Kessel, M.-N. Duma, M. Oechsner, C. Straube, S.E. Combs, Cavity volume changes after surgery of a brain metastasis—consequences for stereotactic radiation therapy, Strahlenther Onkol. 195 (2019) 207–217. https://doi.org/10.1007/s00066-018-1387-y.
[11] M. Guckenberger, W.W. Baus, O. Blanck, S.E. Combs, J. Debus, R. Engenhart-Cabillic, T. Gauer, A.L. Grosu, D. Schmitt, S. Tanadini-Lang, C. Moustakis, Definition and quality requirements for stereotactic radiotherapy: consensus statement from the DEGRO/DGMP Working Group Stereotactic Radiotherapy and Radiosurgery, Strahlenther Onkol. 196 (2020) 417–420. https://doi.org/10.1007/s00066-020-01603-1.
[12] R.J. Weil, G.G. Mavinkurve, S.T. Chao, M.A. Vogelbaum, J.H. Suh, M. Kolar, S.A. Toms, Intraoperative radiotherapy to treat newly diagnosed solitary brain metastasis: initial experience and long-term outcomes, JNS. 122 (2015) 825–832. https://doi.org/10.3171/2014.11.JNS1449.
[13] C.P. Cifarelli, S. Brehmer, J.A. Vargo, J.D. Hack, K.H. Kahl, G. Sarria-Vargas, F.A. Giordano, Intraoperative radiotherapy (IORT) for surgically resected brain metastases: outcome analysis of an international cooperative study, J Neurooncol. 145 (2019) 391–397. https://doi.org/10.1007/s11060-019-03309-6.
[14] Y. Kanda, Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics, Bone Marrow Transplant. 48 (2013) 452–458. https://doi.org/10.1038/bmt.2012.244.
[15] L. Gaspar, C. Scott, M. Rotman, S. Asbell, T. Phillips, T. Wasserman, W.G. McKenna, R. Byhardt, Recursive partitioning analysis (RPA) of prognostic factors in three radiation therapy oncology group (RTOG) brain metastases trials, International Journal of Radiation Oncology*Biology*Physics. 37 (1997) 745–751. https://doi.org/10.1016/S0360-3016(96)00619-0.
[16] C. Brennan, T.J. Yang, P. Hilden, Z. Zhang, K. Chan, Y. Yamada, T.A. Chan, S.C. Lymberis, A. Narayana, V. Tabar, P.H. Gutin, Å. Ballangrud, E. Lis, K. Beal, A Phase 2 Trial of Stereotactic Radiosurgery Boost After Surgical Resection for Brain Metastases, International Journal of Radiation Oncology*Biology*Physics. 88 (2014) 130–136. https://doi.org/10.1016/j.ijrobp.2013.09.051.
[17] S.E. Combs, A. Bilger, C. Diehl, E. Bretzinger, H. Lorenz, O. Oehlke, H.M. Specht, A. Kirstein, A.-L. Grosu, Multicenter analysis of stereotactic radiotherapy of the resection cavity in patients with brain metastases, Cancer Med. 7 (2018) 2319–2327. https://doi.org/10.1002/cam4.1477.
[18] T. Gutschenritter, V.A. Venur, S.E. Combs, B. Vellayappan, A.P. Patel, M. Foote, K.J. Redmond, T.J.C. Wang, A. Sahgal, S.T. Chao, J.H. Suh, E.L. Chang, R.G. Ellenbogen, S.S. Lo, The Judicious Use of Stereotactic Radiosurgery and Hypofractionated Stereotactic Radiotherapy in the Management of Large Brain Metastases, Cancers. 13 (2020) 70. https://doi.org/10.3390/cancers13010070.
[19] J. Hsieh, P. Elson, B. Otvos, J. Rose, C. Loftus, G. Rahmathulla, L. Angelov, G.H. Barnett, R.J. Weil, M.A. Vogelbaum, Tumor Progression in Patients Receiving Adjuvant Whole-Brain Radiotherapy vs Localized Radiotherapy After Surgical Resection of Brain Metastases, Neurosurgery. 76 (2015) 411–420. https://doi.org/10.1227/NEU.0000000000000626.
[20] S. Scharl, K.A. Kessel, C. Diehl, J. Gempt, B. Meyer, C. Zimmer, C. Straube, S.E. Combs, Is local radiotherapy a viable option for patients with an opening of the ventricles during surgical resection of brain metastases?, Radiat Oncol. 15 (2020) 276. https://doi.org/10.1186/s13014-020-01725-x.
[21] A. Bilger, E. Bretzinger, J. Fennell, C. Nieder, H. Lorenz, O. Oehlke, A.-L. Grosu, H.M. Specht, S.E. Combs, Local control and possibility of tailored salvage after hypofractionated stereotactic radiotherapy of the cavity after brain metastases resection, Cancer Med. 7 (2018) 2350–2359. https://doi.org/10.1002/cam4.1486.
[22] A. Mahajan, S. Ahmed, M.F. McAleer, J.S. Weinberg, J. Li, P. Brown, S. Settle, S.S. Prabhu, F.F. Lang, N. Levine, S. McGovern, E. Sulman, I.E. McCutcheon, S. Azeem, D. Cahill, C. Tatsui, A.B. Heimberger, S. Ferguson, A. Ghia, F. Demonte, S. Raza, N. Guha-Thakurta, J. Yang, R. Sawaya, K.R. Hess, G. Rao, Post-operative stereotactic radiosurgery versus observation for completely resected brain metastases: a single-centre, randomised, controlled, phase 3 trial, The Lancet Oncology. 18 (2017) 1040–1048. https://doi.org/10.1016/S1470-2045(17)30414-X.
[23] A. Wijetunga, D. Jayamanne, R. Cook, J. Parkinson, N. Little, J. Curtis, C. Brown, M. Back, Hypofractionated adjuvant surgical cavity radiotherapy following resection of limited brain metastasis, Journal of Clinical Neuroscience. 82 (2020) 155–161. https://doi.org/10.1016/j.jocn.2020.10.041.
[24] V. Nardone, S. Nanni, P. Pastina, C. Vinciguerra, A. Cerase, P. Correale, C. Guida, A. Giordano, P. Tini, A. Reginelli, S. Cappabianca, L. Pirtoli, Role of perilesional edema and tumor volume in the prognosis of non-small cell lung cancer (NSCLC) undergoing radiosurgery (SRS) for brain metastases, Strahlenther Onkol. 195 (2019) 734–744. https://doi.org/10.1007/s00066-019-01475-0.
[25] F.A. Giordano, S. Brehmer, Y. Abo-Madyan, G. Welzel, E. Sperk, A. Keller, F. Schneider, S. Clausen, C. Herskind, P. Schmiedek, F. Wenz, INTRAGO: intraoperative radiotherapy in glioblastoma multiforme – a Phase I/II dose escalation study, BMC Cancer. 14 (2014) 992. https://doi.org/10.1186/1471-2407-14-992.
[26] J.A. Vargo, K.M. Sparks, R. Singh, G.M. Jacobson, J.D. Hack, C.P. Cifarelli, Feasibility of dose escalation using intraoperative radiotherapy following resection of large brain metastases compared to post-operative stereotactic radiosurgery, J Neurooncol. 140 (2018) 413–420. https://doi.org/10.1007/s11060-018-2968-4.
[27] Q. Liu, F. Schneider, L. Ma, F. Wenz, C. Herskind, Relative Biologic Effectiveness (RBE) of 50 kV X-rays Measured in a Phantom for Intraoperative Tumor-Bed Irradiation, International Journal of Radiation Oncology*Biology*Physics. 85 (2013) 1127–1133. https://doi.org/10.1016/j.ijrobp.2012.08.005.
[28] C. Herskind, F. Wenz, F.A. Giordano, Immunotherapy Combined with Large Fractions of Radiotherapy: Stereotactic Radiosurgery for Brain Metastases—Implications for Intraoperative Radiotherapy after Resection, Front. Oncol. 7 (2017) 147. https://doi.org/10.3389/fonc.2017.00147.
[29] C. Herskind, F. Wenz, Is There More to Intraoperative Radiotherapy Than Physical Dose?, International Journal of Radiation Oncology*Biology*Physics. 74 (2009) 976–977. https://doi.org/10.1016/j.ijrobp.2009.02.042.
[30] L. Wilke, N. Andratschke, O. Blanck, T.B. Brunner, S.E. Combs, A.-L. Grosu, C. Moustakis, D. Schmitt, W.W. Baus, M. Guckenberger, ICRU report 91 on prescribing, recording, and reporting of stereotactic treatments with small photon beams: Statement from the DEGRO/DGMP working group stereotactic radiotherapy and radiosurgery, Strahlenther Onkol. 195 (2019) 193–198. https://doi.org/10.1007/s00066-018-1416-x.
[31] C. Herskind, J. Griebel, U. Kraus-Tiefenbacher, F. Wenz, Sphere of Equivalence—A Novel Target Volume Concept for Intraoperative Radiotherapy Using Low-Energy X Rays, International Journal of Radiation Oncology*Biology*Physics. 72 (2008) 1575–1581. https://doi.org/10.1016/j.ijrobp.2008.08.009.
[32] S. Uhlig, A. Wuhrer, S. Berlit, B. Tuschy, M. Sütterlin, K. Bieback, Intraoperative radiotherapy for breast cancer treatment efficiently targets the tumor bed preventing breast adipose stromal cell outgrowth, Strahlenther Onkol. 196 (2020) 398–404. https://doi.org/10.1007/s00066-020-01586-z.
[33] A. Keller, M. Doré, H. Cebula, F. Thillays, F. Proust, I. Darié, S.-A. Martin, G. Delpon, F. Lefebvre, G. Noël, D. Antoni, Hypofractionated Stereotactic Radiation Therapy to the Resection Bed for Intracranial Metastases, International Journal of Radiation Oncology*Biology*Physics. 99 (2017) 1179–1189. https://doi.org/10.1016/j.ijrobp.2017.08.014.
[34] K.A. Ahmed, J.M. Freilich, Y. Abuodeh, N. Figura, N. Patel, S. Sarangkasiri, P. Chinnaiyan, H.-H.M. Yu, A.B. Etame, N.G. Rao, Fractionated stereotactic radiotherapy to the post-operative cavity for radioresistant and radiosensitive brain metastases, J Neurooncol. 118 (2014) 179–186. https://doi.org/10.1007/s11060-014-1417-2.
[35] J.R. Robbins, S. Ryu, S. Kalkanis, C. Cogan, J. Rock, B. Movsas, J.H. Kim, M. Rosenblum, Radiosurgery to the Surgical Cavity as Adjuvant Therapy for Resected Brain Metastasis, Neurosurgery. 71 (2012) 937–943. https://doi.org/10.1227/NEU.0b013e31826909f2.
[36] F. Pessina, P. Navarria, L. Cozzi, S. Tomatis, A.M. Ascolese, C. Franzese, L. Toschi, A. Santoro, F. De Rose, D. Franceschini, L. Bello, M. Scorsetti, Outcome appraisal of patients with limited brain metastases (BMs) from non small cell lung cancer (NSCLC) treated with different local therapeutic strategies: a single institute evaluation, BJR. 90 (2017) 20170022. https://doi.org/10.1259/bjr.20170022.
[37] K.R. Patel, S.H. Burri, D. Boselli, J.T. Symanowski, A.L. Asher, A. Sumrall, R.W. Fraser, R.H. Press, J. Zhong, R.J. Cassidy, J.J. Olson, W.J. Curran, H.-K.G. Shu, I.R. Crocker, R.S. Prabhu, Comparing pre-operative stereotactic radiosurgery (SRS) to post-operative whole brain radiation therapy (WBRT) for resectable brain metastases: a multi-institutional analysis, J Neurooncol. 131 (2017) 611–618. https://doi.org/10.1007/s11060-016-2334-3.
[38] J. Kerschbaumer, D. Pinggera, B. Holzner, M. Delazer, T. Bodner, E. Karner, L. Dostal, I. Kvitsaridze, D. Minasch, C. Thomé, M. Seiz-Rosenhagen, M. Nevinny-Stickel, C.F. Freyschlag, Sector Irradiation vs. Whole Brain Irradiation After Resection of Singular Brain Metastasis—A Prospective Randomized Monocentric Trial, Front. Oncol. 10 (2020) 591884. https://doi.org/10.3389/fonc.2020.591884.
[39] E.W. Sankey, V. Tsvankin, M.M. Grabowski, G. Nayar, K.A. Batich, A. Risman, C.D. Champion, A.K.S. Salama, C.R. Goodwin, P.E. Fecci, Operative and peri‐operative considerations in the management of brain metastasis, Cancer Med. 8 (2019) 6809–6831. https://doi.org/10.1002/cam4.2577.
[40] A.J. Patel, D. Suki, M.A. Hatiboglu, V.Y. Rao, B.D. Fox, R. Sawaya, Impact of surgical methodology on the complication rate and functional outcome of patients with a single brain metastasis, JNS. 122 (2015) 1132–1143. https://doi.org/10.3171/2014.9.JNS13939.
[41] K. Schmieder, U. Keilholz, S. Combs, The Interdisciplinary Management of Brain Metastases, Deutsches Aerzteblatt Online. (2016). https://doi.org/10.3238/arztebl.2016.0415.
[42] R. Bodensohn, I. Hadi, D.F. Fleischmann, S. Corradini, N. Thon, J. Rauch, C. Belka, M. Niyazi, Bevacizumab as a treatment option for radiation necrosis after cranial radiation therapy: a retrospective monocentric analysis, Strahlenther Onkol. 196 (2020) 70–76. https://doi.org/10.1007/s00066-019-01521-x.